- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07587424
Impact of Dietary Fibre Supplementation on Gut Symptoms in Healthy Participants (KiVa)
The Effect of Dietary Fibre Supplementation on Gastrointestinal Symptoms in Healthy Participants - KiVa-trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The objective of this dietary intervention is to examine the effects of different dietary fibre types on gastrointestinal symptoms in apparently healthy adults and to investigate how these effects relate to the composition and functional capacity of the gut microbiota.
The study is designed as a randomized, crossover intervention trial with a total duration of approximately 6 weeks. A 5-day run-in phase is carried out to stabilize baseline dietary patterns and ensure adherence to study procedures. During the intervention, each participant consumes 3 different fibre-rich products, with each product administered for 4 consecutive days (referred to as a "fibre period"). Each fibre period is separated by a 10-day washout period.
Participants (n=28) are apparently healthy adult males and females aged 18-65 years who experience gastrointestinal/ digestive discomfort during or after eating. Individuals without such symptoms are unlikely to exhibit measurable responses, which would limit the ability to address the study's primary research questions.
During the 4-day fibre period, the daily fibre dose provided by the study product is 20 g for women and 25 g for men (corresponding to 2.5 g of fibre per MJ of energy intake, assuming daily energy intake of 8 MJ for women and 10 MJ for men). During the trial, participants consume three structurally different types of dietary fibre: cellulose (poorly fermentable fibre; microcrystalline cellulose), beta-glucan rich fibre (oat bran-based fibre product), and arabinoxylan rich fibre (rye bran-based fibre product). Participants are randomly assigned into one of the six predefined intervention sequences, which represent all possible orders of exposure to the 3 fibre products. Sequence allocation will be generated prior to enrolment, and participants will receive each fibre-rich test product in a randomized order. Participants are instructed to keep the rest of their diet as habitual as possible during the study. Regular use of dietary supplements must be discontinued for the study duration
Participants report their daily GI symptoms as well as perceived stress and mood through a symptom questionnaire using a mobile app. A total of nine GI symptoms are reported (i.e., stomach/ abdominal pain, stomach cramps, bloating, flatulence, borborygmus, nausea, heartburn, discomfort in the upper abdomen/ unpleasant sensation of fullness following eating, a sudden need to defecate), and their severity of symptoms is assessed on a 0-100 VAS scale. Participants report daily the number of bowel movements through the online form, as well as their daily amount of physical activity. In addition, physical activity is assessed using an accelerometer. Dietary intake is assessed by food records (3-day food records during the run-in period and 2-day food records during each fibre period).
Stool samples are used for the analysis of the gut microbiota and metabolome. Additionally, the the effects of different fibre types on metabolic profiles in blood, urine, and stool samples (including SCFAs), as well as on gases in exhaled breath will be analysed.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Anne-Maria Pajari, Professor
- Número de telefone: +358294158203
- E-mail: anne-maria.pajari@helsinki.fi
Estude backup de contato
- Nome: Maija Marttinen, PhD
- Número de telefone: +358294158209
- E-mail: maija.marttinen@helsinki.fi
Locais de estudo
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlândia
- Department of Food and Nutrition, University of Helsinki
-
Contato:
- Anne-Maria Pajari, Professor
- Número de telefone: +358294158203
- E-mail: anne-maria.pajari@helsinki.fi
-
Contato:
- Maija Marttinen, PhD
- Número de telefone: +358294158209
- E-mail: maija.marttinen@helsinki.fi
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- healthy male and female
- aged 18-65 years
- experience gastrointestinal discomfort during or after eating
- willing to commit to the 6-week study period and follow the study schedule.
Exclusion Criteria:
- Body mass index ≤ 18.5 or ≥ 35 kg/m².
- Inflammatory bowel diseases, irritable bowel syndrome (IBS), celiac disease, endocrine or lipid metabolism disorders, liver or kidney diseases, cancer within the past 5 years, eating disorders.
- Medication for gastrointestinal symptoms, bowel function, diabetes, or hypercholesterolemia.
- Regular or recent use of antibiotics (within the last 3 months).
- Food allergies to the ingredients of the study products.
- Heavy, long-duration exercise several times a week.
- Smoking, use of snus or nicotine pouches.
- Planned or ongoing pregnancy or breastfeeding.
- In addition, the site-specific principal investigator may exclude a person due to any illness, medication, or factor they deem relevant for the participant's health and safety or for the conduct of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cellulose
poorly fermentable fibre, "negative control"
|
Microcrystalline cellulose; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days
|
|
Experimental: Oat fibre
fibre-rich product from oat bran
|
Oat bran-based fibre product; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days
|
|
Experimental: Rye fibre
fibre-rich product from rye bran
|
Rye bran-based fibre product; daily dose of fibre from the study product 20 g for females and 25 g for males on 4 consecutive days
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intensity of gastrointestinal symptoms, total score
Prazo: 6 weeks Differences between the fibre periods and fibre periods and run-in period will be compared.
|
The composite score of the intensity of individual gastrointestinal symptoms reported on a VAS scale by the participants.
|
6 weeks Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of stomach/ abdominal pain
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced stomach/ abdominal pain reported on a VAS scale from zero (no pain) to 100 (very intense pain) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of bloating
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced bloatingreported on a VAS scale from zero (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of stomach cramps
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared
|
Intensity of experienced stomach cramps reported on a VAS scale from zero (no pain) to 100 (very intense pain) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared
|
|
Intensity of flatulence
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced flatulence reported on a VAS scale from zero (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of borborygmus
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced borborygmus reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of nausea
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced nausea reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of heartburn
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced heartburn reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of discomfort in the upper abdomen or unpleasant sensation of fullness following eating
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced discomfort or unpleasant sensation reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Intensity of a sudden need to defecate
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Intensity of experienced discomfort or unpleasant sensation reported on a VAS scale from 0 (no symptoms) to 100 (very intense symptoms) by the participants on daily basis.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Composition and function of gut microbiome
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Microbiota-related analyses of the collected stool samples are carried out using DNA-based methods
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Number of bowel movements
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Number of bowel movements reported by participants on daily basis using a mobile app.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Breath gases
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Hydrogen and methane measured from exhaled breath samples during run-in and fibre periods.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Fecal and blood SCFA
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Analysis of short chain fatty acids (SCFA) from stool and blood samples
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dietary intake
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
The intake of dietary fibre and nutrients calculated from food records during run-in and fibre periods.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Physical activity
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Level of physical activity and inactivity determined using an accelerometer during run-in and fibre periods.
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
|
Metabolomics from feces, blood and urine
Prazo: 6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Targeted/untargeted analysis of fecal, blood and urine metabolome
|
6 weeks. Differences between the fibre periods and fibre periods and run-in period will be compared.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FIBRE-MATCH Helsinki Pilot
- 101161484 (Número de outro subsídio/financiamento: European Innovation Council (EIC))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .